Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma

•RAD51 nuclear loss is weakly associated with high TILs in curatively resected NSCLC•RAD51 nuclear loss is weakly associated with high PD-L1 expression in resected NSCLC•Both associations were more pronounced after exposure to chemo- or radiotherapy•TILs and RAD51 nuclear loss both have prognostic v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-09, Vol.147, p.30-38
Hauptverfasser: Gachechiladze, Mariam, Škarda, Josef, Skanderová, Daniela, Überall, Ivo, Kolek, Vítězslav, Smičkova, Petra, Vojta, Petr, Vbrková, Jana, Hajdúch, Marián, Shani, Ilay, Kolář, Zdeněk, Stahel, Rolf, Weder, Walter, Rulle, Undine, Soltermann, Alex, Joerger, Markus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue
container_start_page 30
container_title Lung cancer (Amsterdam, Netherlands)
container_volume 147
creator Gachechiladze, Mariam
Škarda, Josef
Skanderová, Daniela
Überall, Ivo
Kolek, Vítězslav
Smičkova, Petra
Vojta, Petr
Vbrková, Jana
Hajdúch, Marián
Shani, Ilay
Kolář, Zdeněk
Stahel, Rolf
Weder, Walter
Rulle, Undine
Soltermann, Alex
Joerger, Markus
description •RAD51 nuclear loss is weakly associated with high TILs in curatively resected NSCLC•RAD51 nuclear loss is weakly associated with high PD-L1 expression in resected NSCLC•Both associations were more pronounced after exposure to chemo- or radiotherapy•TILs and RAD51 nuclear loss both have prognostic value in curatively resected NSCLC DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p < 0.0001), CD68 (r = ‒0.326, p < 0.001), CD3 (r = ‒0.266, p < 0.001) and CD8 (r = ‒0.102, p < 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42−0.76, p < 0.001). Similar results have been seen for CD3, CD8 and CD68. In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.
doi_str_mv 10.1016/j.lungcan.2020.06.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423516345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500220304992</els_id><sourcerecordid>2423516345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-f070a02c401854955f28e862406df6d26467e592ebe013f6a8592fc7f324f3a23</originalsourceid><addsrcrecordid>eNqFkctuEzEUhi0EoqHwCCAvy2KCL2PPZIWihkKlCCpU1pbrOU4czdiD7Snk1fp0eJTAlo2PffT9PpcfobeULCmh8sNh2U9-Z7RfMsLIksglYeIZWtC2YVXLOXuOFoVbVYIQdoFepXQghDaUrF6iC86k4LKhC_R0F8POh5SdwY-6nwAHi_M0hFg5b12fo87O73B_HMZ9MMcMCV_d327Te6x9h_MeXMQ6pWBcAYPHv1ze47tNtaUYfo8RUpqzM7v5usYRRl0EYwwZnMff1xtBcbmMRQw-p5O8qMBk6LAPvkqD7ntsoBzzxNjoaJwPg36NXljdJ3hzjpfox82n--sv1fbb59vr9bYyXIpcWdIQTZipCW1FvRLCshZayWoiOys7JmvZgFgxeABCuZW6LQ9rGstZbblm_BJdnf4tXf-cIGU1uDT3oz2EKSlWMy6o5LUoqDihJoaUIlg1RjfoeFSUqNk2dVBn29RsmyJSFduK7t25xPQwQPdP9denAnw8AVAGfXQQVTJlYQY6F8uqVBfcf0r8AWaZrbU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2423516345</pqid></control><display><type>article</type><title>Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gachechiladze, Mariam ; Škarda, Josef ; Skanderová, Daniela ; Überall, Ivo ; Kolek, Vítězslav ; Smičkova, Petra ; Vojta, Petr ; Vbrková, Jana ; Hajdúch, Marián ; Shani, Ilay ; Kolář, Zdeněk ; Stahel, Rolf ; Weder, Walter ; Rulle, Undine ; Soltermann, Alex ; Joerger, Markus</creator><creatorcontrib>Gachechiladze, Mariam ; Škarda, Josef ; Skanderová, Daniela ; Überall, Ivo ; Kolek, Vítězslav ; Smičkova, Petra ; Vojta, Petr ; Vbrková, Jana ; Hajdúch, Marián ; Shani, Ilay ; Kolář, Zdeněk ; Stahel, Rolf ; Weder, Walter ; Rulle, Undine ; Soltermann, Alex ; Joerger, Markus</creatorcontrib><description>•RAD51 nuclear loss is weakly associated with high TILs in curatively resected NSCLC•RAD51 nuclear loss is weakly associated with high PD-L1 expression in resected NSCLC•Both associations were more pronounced after exposure to chemo- or radiotherapy•TILs and RAD51 nuclear loss both have prognostic value in curatively resected NSCLC DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p &lt; 0.0001), CD68 (r = ‒0.326, p &lt; 0.001), CD3 (r = ‒0.266, p &lt; 0.001) and CD8 (r = ‒0.102, p &lt; 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42−0.76, p &lt; 0.001). Similar results have been seen for CD3, CD8 and CD68. In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2020.06.025</identifier><identifier>PMID: 32653671</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>B7-H1 Antigen - genetics ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - therapy ; DNA Repair ; Humans ; Lung Neoplasms - genetics ; Lung Neoplasms - therapy ; Lymphocytes, Tumor-Infiltrating ; Neoadjuvant ; PD-L1 ; Prognosis ; Prognostic ; RAD51 ; Rad51 Recombinase - genetics ; Switzerland ; Tumor infiltrating lymphocytes</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.30-38</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-f070a02c401854955f28e862406df6d26467e592ebe013f6a8592fc7f324f3a23</citedby><cites>FETCH-LOGICAL-c365t-f070a02c401854955f28e862406df6d26467e592ebe013f6a8592fc7f324f3a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2020.06.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32653671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gachechiladze, Mariam</creatorcontrib><creatorcontrib>Škarda, Josef</creatorcontrib><creatorcontrib>Skanderová, Daniela</creatorcontrib><creatorcontrib>Überall, Ivo</creatorcontrib><creatorcontrib>Kolek, Vítězslav</creatorcontrib><creatorcontrib>Smičkova, Petra</creatorcontrib><creatorcontrib>Vojta, Petr</creatorcontrib><creatorcontrib>Vbrková, Jana</creatorcontrib><creatorcontrib>Hajdúch, Marián</creatorcontrib><creatorcontrib>Shani, Ilay</creatorcontrib><creatorcontrib>Kolář, Zdeněk</creatorcontrib><creatorcontrib>Stahel, Rolf</creatorcontrib><creatorcontrib>Weder, Walter</creatorcontrib><creatorcontrib>Rulle, Undine</creatorcontrib><creatorcontrib>Soltermann, Alex</creatorcontrib><creatorcontrib>Joerger, Markus</creatorcontrib><title>Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>•RAD51 nuclear loss is weakly associated with high TILs in curatively resected NSCLC•RAD51 nuclear loss is weakly associated with high PD-L1 expression in resected NSCLC•Both associations were more pronounced after exposure to chemo- or radiotherapy•TILs and RAD51 nuclear loss both have prognostic value in curatively resected NSCLC DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p &lt; 0.0001), CD68 (r = ‒0.326, p &lt; 0.001), CD3 (r = ‒0.266, p &lt; 0.001) and CD8 (r = ‒0.102, p &lt; 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42−0.76, p &lt; 0.001). Similar results have been seen for CD3, CD8 and CD68. In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.</description><subject>B7-H1 Antigen - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>DNA Repair</subject><subject>Humans</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - therapy</subject><subject>Lymphocytes, Tumor-Infiltrating</subject><subject>Neoadjuvant</subject><subject>PD-L1</subject><subject>Prognosis</subject><subject>Prognostic</subject><subject>RAD51</subject><subject>Rad51 Recombinase - genetics</subject><subject>Switzerland</subject><subject>Tumor infiltrating lymphocytes</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctuEzEUhi0EoqHwCCAvy2KCL2PPZIWihkKlCCpU1pbrOU4czdiD7Snk1fp0eJTAlo2PffT9PpcfobeULCmh8sNh2U9-Z7RfMsLIksglYeIZWtC2YVXLOXuOFoVbVYIQdoFepXQghDaUrF6iC86k4LKhC_R0F8POh5SdwY-6nwAHi_M0hFg5b12fo87O73B_HMZ9MMcMCV_d327Te6x9h_MeXMQ6pWBcAYPHv1ze47tNtaUYfo8RUpqzM7v5usYRRl0EYwwZnMff1xtBcbmMRQw-p5O8qMBk6LAPvkqD7ntsoBzzxNjoaJwPg36NXljdJ3hzjpfox82n--sv1fbb59vr9bYyXIpcWdIQTZipCW1FvRLCshZayWoiOys7JmvZgFgxeABCuZW6LQ9rGstZbblm_BJdnf4tXf-cIGU1uDT3oz2EKSlWMy6o5LUoqDihJoaUIlg1RjfoeFSUqNk2dVBn29RsmyJSFduK7t25xPQwQPdP9denAnw8AVAGfXQQVTJlYQY6F8uqVBfcf0r8AWaZrbU</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Gachechiladze, Mariam</creator><creator>Škarda, Josef</creator><creator>Skanderová, Daniela</creator><creator>Überall, Ivo</creator><creator>Kolek, Vítězslav</creator><creator>Smičkova, Petra</creator><creator>Vojta, Petr</creator><creator>Vbrková, Jana</creator><creator>Hajdúch, Marián</creator><creator>Shani, Ilay</creator><creator>Kolář, Zdeněk</creator><creator>Stahel, Rolf</creator><creator>Weder, Walter</creator><creator>Rulle, Undine</creator><creator>Soltermann, Alex</creator><creator>Joerger, Markus</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202009</creationdate><title>Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma</title><author>Gachechiladze, Mariam ; Škarda, Josef ; Skanderová, Daniela ; Überall, Ivo ; Kolek, Vítězslav ; Smičkova, Petra ; Vojta, Petr ; Vbrková, Jana ; Hajdúch, Marián ; Shani, Ilay ; Kolář, Zdeněk ; Stahel, Rolf ; Weder, Walter ; Rulle, Undine ; Soltermann, Alex ; Joerger, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-f070a02c401854955f28e862406df6d26467e592ebe013f6a8592fc7f324f3a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>B7-H1 Antigen - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>DNA Repair</topic><topic>Humans</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - therapy</topic><topic>Lymphocytes, Tumor-Infiltrating</topic><topic>Neoadjuvant</topic><topic>PD-L1</topic><topic>Prognosis</topic><topic>Prognostic</topic><topic>RAD51</topic><topic>Rad51 Recombinase - genetics</topic><topic>Switzerland</topic><topic>Tumor infiltrating lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gachechiladze, Mariam</creatorcontrib><creatorcontrib>Škarda, Josef</creatorcontrib><creatorcontrib>Skanderová, Daniela</creatorcontrib><creatorcontrib>Überall, Ivo</creatorcontrib><creatorcontrib>Kolek, Vítězslav</creatorcontrib><creatorcontrib>Smičkova, Petra</creatorcontrib><creatorcontrib>Vojta, Petr</creatorcontrib><creatorcontrib>Vbrková, Jana</creatorcontrib><creatorcontrib>Hajdúch, Marián</creatorcontrib><creatorcontrib>Shani, Ilay</creatorcontrib><creatorcontrib>Kolář, Zdeněk</creatorcontrib><creatorcontrib>Stahel, Rolf</creatorcontrib><creatorcontrib>Weder, Walter</creatorcontrib><creatorcontrib>Rulle, Undine</creatorcontrib><creatorcontrib>Soltermann, Alex</creatorcontrib><creatorcontrib>Joerger, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gachechiladze, Mariam</au><au>Škarda, Josef</au><au>Skanderová, Daniela</au><au>Überall, Ivo</au><au>Kolek, Vítězslav</au><au>Smičkova, Petra</au><au>Vojta, Petr</au><au>Vbrková, Jana</au><au>Hajdúch, Marián</au><au>Shani, Ilay</au><au>Kolář, Zdeněk</au><au>Stahel, Rolf</au><au>Weder, Walter</au><au>Rulle, Undine</au><au>Soltermann, Alex</au><au>Joerger, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2020-09</date><risdate>2020</risdate><volume>147</volume><spage>30</spage><epage>38</epage><pages>30-38</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>•RAD51 nuclear loss is weakly associated with high TILs in curatively resected NSCLC•RAD51 nuclear loss is weakly associated with high PD-L1 expression in resected NSCLC•Both associations were more pronounced after exposure to chemo- or radiotherapy•TILs and RAD51 nuclear loss both have prognostic value in curatively resected NSCLC DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p &lt; 0.0001), CD68 (r = ‒0.326, p &lt; 0.001), CD3 (r = ‒0.266, p &lt; 0.001) and CD8 (r = ‒0.102, p &lt; 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42−0.76, p &lt; 0.001). Similar results have been seen for CD3, CD8 and CD68. In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>32653671</pmid><doi>10.1016/j.lungcan.2020.06.025</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0169-5002
ispartof Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.30-38
issn 0169-5002
1872-8332
language eng
recordid cdi_proquest_miscellaneous_2423516345
source MEDLINE; Elsevier ScienceDirect Journals
subjects B7-H1 Antigen - genetics
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - therapy
DNA Repair
Humans
Lung Neoplasms - genetics
Lung Neoplasms - therapy
Lymphocytes, Tumor-Infiltrating
Neoadjuvant
PD-L1
Prognosis
Prognostic
RAD51
Rad51 Recombinase - genetics
Switzerland
Tumor infiltrating lymphocytes
title Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T13%3A00%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20tumor-infiltrating%20lymphocytes%20(TILs)%20and%20their%20association%20with%20PD-L1%20expression%20and%20DNA%20repair%20protein%20RAD51%20in%20patients%20with%20resected%20non-small%20cell%20lung%20carcinoma&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Gachechiladze,%20Mariam&rft.date=2020-09&rft.volume=147&rft.spage=30&rft.epage=38&rft.pages=30-38&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2020.06.025&rft_dat=%3Cproquest_cross%3E2423516345%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2423516345&rft_id=info:pmid/32653671&rft_els_id=S0169500220304992&rfr_iscdi=true